Clicky

Valeo Pharma Inc(VPHIF)

Description: Valeo Pharma Inc. acquires and markets specialty products in the United States and Canada. Its product portfolio includes Synacthen, a neurology therapeutic for the treatment of severe multiple sclerosis and gout; and M-Eslon, an extended release morphine sulphate used for pain management. The company also offers Ondansetron ODT for prevention of nausea and vomiting caused by cancer chemotherapy; Benztropine, an anticholinergic agent used for the treatment of Parkinson's disease; and Onstryv, a safinamide tablet used to treat idiopathic Parkinson's disease. In addition, it develops Ethacrynate Sodium, a loop diuretic used to treat high blood pressure, as well as the swelling caused by diseases, such as congestive heart failure, liver failure, and kidney failure. The company was founded in 2003 and is headquartered in Kirkland, Canada.


Keywords: Cancer Drugs Pain Psychoactive Drugs Chemotherapy Parkinson's Disease Pain Management Treatment Of Parkinson's Disease Antiemetics Nausea Congestive Heart Failure Gout High Blood Pressure Kidney Failure Tardive Dyskinesia Safinamide Idiopathic Parkinson's Disease Liver Failure Muscarinic Antagonists

Home Page: www.valeopharma.com

16667 Hymus Boulevard
Kirkland, QC H9H 4R9
Canada
Phone: 514 694 0150


Officers

Name Title
Mr. Steven Saviuk CA Vice Chairman & CEO
Mr. Luc Mainville M.B.A, M.B.A. Sr. VP & CFO
Mr. Guy-Paul Allard VP of Legal Affairs & Corp. Sec.
Mr. Frederic Dumais Director of Communications & Investor Relations
Mr. Kyle Steiger Sr. VP & Chief Commercial Officer
Mr. Jean Francois Fournier Head of Ophthalmology Bus. Unit

Exchange: OTCQB

Country: US

Currency: US Dollar ($)

Forward PE: 21.2314
Trailing PE: 0
Price-to-Book MRQ: 66.7468
Price-to-Sales TTM: 2.1358
IPO Date:
Fiscal Year End: October
Full Time Employees: 100
Back to stocks